Last
Update:
March 05, 2007
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
-
PDF CONFERENCE POSTER
Drug
Resistance Outcomes at 48 Weeks in the OK04 Trial: A Comparative
Trial of Single-drug Maintenance
Therapy with Lopinavir/Ritonavir vs Triple Therapy with LPV/r
J Arribas, F
Pulido, R Delgado, et al
PDF
Poster
Abstract
-
PDF CONFERENCE POSTER
Long-term
Follow-up of 414 HIV-infected Romanian Children and Adolescents
Receiving
Lopinavir/Ritonavir-containing HAART
M Kline, S
Rugina, M Ilie, et al
PDF
Poster
Abstract-
PDF CONFERENCE POSTER
Single-agent Therapy with Lopinavir/ritonavir Controls HIV-1 Viral
Replication in the
Central Nervous System
RF Yeh, S Letendre, I Novak, et al
PDF Poster
Abstract-
PDF CONFERENCE POSTER
Lopinavir/Ritonavir Monotherapy in 2 Clinical Trials Comparing LPV/r
Monotherapy vs
Triple Therapy with LPV/r (OK and OK04 Trials)
F Pulido, J Arribas, J González-Garcia, et al
PDF Poster
Abstract
-
PDF CONFERENCE POSTER
Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir,
Darunavir, Lopinavir, and Tipranavir of HIV-2
Clinical Isolates from the French ANRS HIV-2 Cohort
D Desbois, G
Peytavin, S Matheron, et al
PDF Poster
Abstract
PDF CONFERENCE POSTER
Predictors of Loss of Virologic Response in Subjects Who
Deintensified to Lopinavir/ritonavir
Monotherapy After Achieving Plasma HIV-1 RNA<50 copies/mL on
Lopinavir/ritonavir Plus
Zidovudine/lamivudine
R Campo, BA da Silva, L Cotte, et al
PDF Poster
Abstract
-
PDF CONFERENCE POSTER
Low-Level Viremia Decays Over 7+ Years to a Residual Level
Correlated with Baseline
HIV-1 RNA
M King, S Palmer, A Wiegand, et al
PDF Poster
Abstract
-
Randomized Comparison in Treatment-naïve Patients of Once-daily vs
Twice-daily Lopinavir/ritonavir-
based ART and Comparison of Once-daily Self-administered vs Directly
Observed Therapy
D Mildvan, C Tierney, R Gross, et
al
-
Concentrations of Lopinavir and Ritonavir in Hair Are Strongly
Correlated with Virologic Success
M Gandhi, N Ameli, P Bacchetti, et al
-
Drug-drug Interaction between Lopinavir/Ritonavir and Rosuvastatin
D Hoody, JJ.
Kiser, J Predhomme, et al
-
Pharmacokinetics and 24-Week Efficacy and Safety of
Lopinavir/Ritonavir in HIV-1-infected Infants
<6 Weeks of Age
J Pinto, B
Robbins, J Chen, et al
-
Sex Differences in Lopinavir/Ritonavir Soft Gel Capsule
Pharmacokinetics among HIV-infected Females
and Males
O Umeh, J
Currier, J G Park, et al
-
Pharmacokinetics of High-dose Lopinavir/Ritonavir with and without
Saquinavir or NNRTI in HIV-infected
Pediatric and Adolescent Patients Previously Treated with PI
B Robbins, P
Havens, E Capparelli, et al
-
Lopinavir Protein Binding during Pregnancy
F Aweeka, A Stek,
B Best, et al
-
Pharmacokinetics and Pharmacodynamics of a Double-boosted PI Regimen
of Saquinavir and
Lopinavir/Ritonavir in Treatment-naive HIV-1-infected Adults
J van der Lugt, S Autar, S Autar, et al
-
Reduced Lopinavir Exposure during Pregnancy: A Case Control Study
G Peytavin, S
Pierre-François, B Cassard, et al
-
Plasma Concentrations of Efavirenz and Lopinavir in Children with
and without Rifampicin-based
Anti-TB Treatment
Y Ren, J Nuttall,
C Egbers, et al
-
Lopinavir Drug Monitoring in 36 Pregnant Women
Marie-Aude
Khuong-Josses, A Boussaïri, C Palette, D Méchali
-
Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with
LPV/r + ZDV/3TC Induction followed
by
LPV/r Monotherapy Compared with EFV + ZDV/3TC
DW Cameron, B da
Silva, J Arribas
-
PDF CONFERENCE POSTER
Response to Kaletra-based Second-line Drug Regimen in HIV-1 Patients
in Nigeria
G Onwuegbuzie, J
Idoko, O Agbaji, et al
PDF Poster
Abstract
|
|
KLS
Main Page